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Introduction
Epilepsy is a heterogenous condition with a range of aetiologies, seizure types, severity and prognoses. Uncontrolled seizures may devastate the patients' confidence, independence or career and are associated with increased morbidity and mortality. Standard AEDs are effective in about 70% of patients 1 while newly available AEDs further improve seizure free outcomes and by providing greater scope to tailor treatment to the individual may reduce drug *Correspondence to: Patricia G. Hosking, University College London Hospitals NHS Trust, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
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side effects 2 . Improving seizure control and minimizing AED side effects are key factors in improving the quality of life among people with epilepsy 3 . However, by virtue of a greater choice, new AEDs also complicate treatment decisions, and increase the number of likely drug combinations, potential drug interactions and AED side effects. AEDs may be seizure specific, may precipitate or exacerbate other conditions, render co-medication less effective, and should be used with caution in different patient groups. Complications may be prevented or minimised with specialist management but specialists in epilepsy remain scarce. Despite the recent expansion of knowledge in epilepsy and it's subsequent development into a subspecialty of neurology there has been little corresponding increase in epilepsy content or the duration of clinical training in neurology. The metabolism rate of the AED or co-medication may be altered by a drug which induces or inhibits liver enzymes and this will affect its efficacy or tolerability. PHT and VPA are both highly protein bound and easily displaced by other highly protein bound drugs while PHT, which has non-linear kinetics, can rapidly cause toxicity following a small dose increase 6 . In the late 20th century, the 'new' AEDs, Vigabatrin (VGB), Lamotrigine (LTG), Topiramate (TPM), Gabapentin (GBP), Oxcarbazepine (OXC), Tiagabine (TGB) and Levetiracetam (LEV) became available. Most have improved pharmacokinetics including linear kinetics, little or no protein binding or liver metabolism and longer half-lives 7 . There are exceptions including LTG, which is extensively metabolised by the liver. Concomitant VPA dosing inhibits it's metabolism which may double the Lamotrigine elimination half-life, whereas its half-life is reduced when co-administered with enzyme inducers such as CBZ or PHT. TPM, which also undergoes some liver metabolism, inhibits a P450 enzyme involved in the metabolism of PHT. When Topiramate is added to PHT, plasma concentrations of PHT are increased by up to 25%, whereas concentrations of TPM are reduced by up to 50% when PHT or CBZ are added 8 . Dose adjustments are required to compensate for these interactions. Tiagabine is highly protein bound and may be displaced by other highly protein bound drugs and as GBP has a short half-life, it requires three times daily dosing. Oxcarbazepine was developed to provide a chemical compound similar to CBZ but with fewer adverse effects and improved pharmacokinetics. It has reduced enzyme induction and no auto induction but like other enzyme inducing AEDs, does reduce the efficacy of the oral contraceptive pill 9 .
Special groups
As well as their improved pharmacokinetics new AEDs are generally better tolerated, however, like standard AEDs a high starting dose and rapid introduction often precipitate or worsen side effects. LTG commonly causes an allergic reaction that may develop into Stevens Johnson reaction 10 . Nausea, fatigue, headache, dizziness, diplopia, ataxia, slowed cognition and mood changes are typical AED side effects that may occur during the early introduction stage or after a dose increase 11 . All AEDs carry specific risks to patients of different gender, ages and with concomitant pathology. Children are more at risk of VPA-related hepatic disease, or PHT induced coarsening of facial features, gum hypertrophy and hirsutism 12 . Barbiturate and benzodiazepines commonly cause drooling, sedation and disturbances in behaviour, mood and cognition 13 .
VPA is associated with obesity, and in women polycystic ovaries, menstrual irregularities, hyperandrogenism and hyperinsulinaemia although further evidence is pending 14 . Hepatic enzyme inducing AEDs interfere with the efficacy of hormonal contraception, and increase the risk of bone metabolic disorders such as osteomalacia and osteopenia 15 . They may cause Vitamin K deficiency, predisposing the newborn to haemorrhagic disease 16 . Many of the standard AEDs have anti-folate effects and are teratogenic. Malformations in neonates exposed to AEDs in early development include orofacial clefts, abdominal atresia, cardiac and skeletal malformations. Neural tube defects have been linked to PHT, CBZ and VPA 17, 18 . While the effects of new AEDs on fetal development, bone health, fertility and the menstrual cycle are not known, LEV, GBP and LTG, and low doses of TPM do not interfere with hormonal contraception. They show little teretogenic effect in animal studies and the early LTG pregnancy register outcomes, show no increased risk over CBZ. LTG may be the AED of choice in elderly patients due to its long half-life which allows once or twice daily dosing, its reduced interactions with co-medications, alleged positive effect on cognition and mood and good side effect profile 19 . However, most AEDs cause side effects, which in the elderly can contribute to falls and fractures or mimic dementia and lead to a premature loss of independence 20, 21 . VGB may cause a permanent visual field deficit and is now rarely prescribed 22 .
Aed efficacy
Most AEDs are more or less efficacious in particular syndromes although the broad spectrum AEDs LEV, TPM and VPA are effective in focal and generalised epilepsy. TPM may completely control infantile spasms 23 and LTG, VPA and TPM are effective in Lennox-Gasteau syndrome and learning disabled patients with refractory epilepsy [24] [25] [26] . Reportedly successful AED combinations include VPA and ESM for refractory absences, CBZ or PHT for refractory GTCSs, and VPA and LTG for refractory generalised epilepsy.
AEDs that can worsen seizures include CBZ, which may worsen typical and atypical absences, myoclonic and atonic seizures 27 , PB, which may worsen absences and trigger absence status and PHT, which may worsen myoclonic and absence seizures 28, 29 . Lamotrigine may exacerbate myoclonic seizures in PME 30, 31 and both Gabapentin and Tiagabine can precipitate episodes of non-convulsive status epilepticus and myoclonic seizures 32 .
Audit and methodology
The epilepsy team at this tertiary referral centre care for over 7000 patients, most with refractory epilepsy, from throughout the United Kingdom. Any patient or their GP has unrestricted access to the ENS by telephone for information and treatment advice. A standard statement ''If there are any medication problems contact the ENS . . . who may advise on medication changes'' is included in the Consultant's letter to the GP. Patients are also referred to the ENS outpatient clinic for information or support and supervision of planned drug changes. The ENS implements AED changes outlined in the treatment plan but can initiate alterations to the regimen. In such instances, the Consultant is informed of the changes and may make further recommendations. Over a 2-week period, 60 treatment-related consultations were provided out of a total 124 contacts. A treatment-related consultation is defined as any consultation where treatment issues, including AEDs, their side effects or seizure control are the main topics discussed. Fifty-five were conducted by telephone, and five were face-to-face in the outpatient clinic. Fifty-eight were with the patient, a carer or a family member and two involved advice to the GP. 17/60 were 'new patients' to the ENS, 36/60 had between 2 and 10 previous ENS contacts, 7/60 had more than 10 previous contacts. One patient had 17 telephone contacts over the previous 2 years. The time interval between the previous Consultant outpatient appointment and contact with the ENS was between 1 and 58 weeks. 46/60 patients had been seen by the Consultant within the previous 16 weeks.
Results
The number of AEDs taken by patients were: nil At the time of contact, 43/60 patients were undertaking changes to the AED regimen. They were: an AED introduction or dose increase 27, an AED withdrawal or dose reduction 10, a simultaneous AED introduction and withdrawal 5, simultaneous increase of 2 AEDs 1.
The telephone contact was due to: AED side effects 17, ongoing seizures 12, recurrence or exacerbation of seizures 11, an improvement in seizures 4, a seizure-related injury 2, AED overdose 1, new seizure presentation 1, prolonged post-ictal aggression 1.
Of the 17/60 with no recent AED change contact was due to: ongoing or worsening seizures 8, AED side effects 6, anxiety about or clarification of AED regimen 3, advice about AED interaction with co-medication 2, post-surgical complication 1.
The AED side effects reported were: headache 9, ataxia 8, cognition problems 8, anxiety 6, low mood 6, visual disturbance 3, fatigue 3, dizziness 2, nausea 2, insomnia 2, eye pain 2, aggression 2, depression 1, irritable mood 1, dysphasia 1, weakness 1, tremor 1, flu symptoms 1.
Treatment response
44/60 patients were given advice about AED treatment. The medication advice included: increase or continue AED dose increases over time 19, reduce AED dose or withdraw AED 16, initiate a new AED 7, maintain AED dose unchanged 5, slow the rate of AED introduction 1, alter dose timing 1, withhold AED dose 1, stop AED and re-challenge following the resolution of symptoms 2, reinstate withdrawn AED 2, repeat AED serum level and review 2, record all seizures in seizure diary 3, add AED prn for seizure cluster or exacerbation 3.
Treatment issues discussed include: clarification of the medication plan 1, post-surgical wound infection 1, post-surgical word-finding difficulties 1, seizure-related hospital admission 2, seizure-related injury 2, compliance 1, management of peri-menstrual seizures 1, resolution of AED side effects 3, improvement in seizures 3, anxiety management 4, treatment options 2, surgery 2, employment 3, prognosis 1, safety precautions and injury prevention 2, independence issues 1.
Where the advice deviated from the Consultant's previous recommendations, AEDs and doses, recent AED changes, seizure history, trigger factors, the problem and recommendations were documented in a letter to the GP that was copied to the patient and filed in the medical records. Thirty-one GP letters were generated from the 60 consultations. Three patients were referred to the counselor, two to the Consultant, two to the ENS outpatient clinic and one to the GP.
Discussion
The majority of patients with refractory epilepsy have complex treatment needs that are often poorly addressed. Most patients attending this hospital had frequent seizures, and often experienced medication side effects and seizure-related injuries. Sixty percent contacted the ENS for urgent medical advice 33 . Patients referred to the ENS generally take multiple AEDs, which include combinations of both standard and new AEDs, and undertake frequent AED dose or drug changes but three times as many patients introducing rather withdrawing an AED contacted the ENS with medication problems.
Ongoing seizures and seizure worsening which occurred both in relation to and in the absence of recent AED changes were the most frequent causes for contact. The advice to the patient was influenced by multiple factors including the AED regimen, past seizure history and AED efficacy, recent AED changes, compliance, exacerbating factors, concomitant medications, past episodes of status epilepticus and other medical conditions. Instructions to adjust the AED regimen were usually accompanied by instructions to telephone the ENS again within a specified time frame if there was no improvement.
AED side effects were the next most frequent reason for contact. Of 23 patients with AED side effects, 16 had mood changes. The treatment advice took into account the severity and duration of side effects, the AED doses, previous dose changes, AED serum levels and dose timing, and adherence to recommended therapy. As symptoms of other medications or medical conditions may mimic AED side effects, information about co-morbidity, treatment with other medications and psychosocial problems also influenced the treatment response. A common interaction between LEV and CBZ was noted. LEV, when added to maximum tolerated doses of CBZ resulted in CBZ side effects, which resolved when the CBZ dose was lowered. A policy of lowering the CBZ dose when LEV is added to a maximum tolerated CBZ dose has subsequently been adopted.
Patients with refractory epilepsy frequently have underlying memory and cognition problems or depression and anxiety, which in addition to ongoing seizure activity, AEDs side effects and psychosocial problems may affect comprehension and compliance with medication. ENS telephone consultations provide an opportunity to access not only new information but reinforce or clarify instructions about AED doses and treatment changes to improve compliance, and intervene to prevent or manage existing problems.
Summary
New knowledge about epilepsy and the availability of new AEDs has made epilepsy treatment more effective but also more complex. The number of AEDs and possible combinations has expanded, as have potential interactions between AEDs and other medications. AED side effects and seizure exacerbation are common treatment problems although treatment-related queries are wide ranging and specialist in nature. As the patient's response to treatment changes, which may be undertaken over a period of weeks or months, can rarely be predicted treatment advice and information may be required within days or months of an outpatient appointment. One way of improving services and the care of people with epilepsy is by giving patients' unrestricted telephone and clinic access to a specialist. This has many advantages for patients including improving the continuity of care and gaining immediate access to treatment advice that is tailored and specific to the individual. Regular follow-up by a specialist optimises care and minimises morbidity and mortality. Telephone access to the ENS who has the authority and experience to advise patients on medication changes is a cost effective way of providing this service and meets many of the recommendations for improving care made by the National Sentinel Clinical Audit of Epilepsy-related Death. To provide a safe and effective service the ENS should have advanced training in epilepsy, access to the patient's medical history and clinical support from a specialist consultant in epilepsy. When planning similar services it should be noted that the advanced nursing skills and training required for this post are in keeping with those of a consultant nurse in epilepsy.
